Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2015-09-06 Investor Presentation
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Invion announces no secondary capital raise 1 page
Investor Presentation Classification · 90% confidence The document is a media announcement from Invion Limited dated September 2015. It announces that the company will not proceed with a secondary capital raise or entitlement offer and lodges a Corporate Presentation for September 2015. The document is short (950 characters) and primarily serves as an announcement rather than the full presentation itself. It does not contain detailed financial data or comprehensive report content. Therefore, it fits best as an Investor Presentation (IP) since it mentions lodging a Corporate Presentation detailing drug development programs and milestones, which aligns with the description of an Investor Presentation focusing on financials, strategy, and market position.
2015-09-06 English
Corporate Presentation - September 2015 35 pages 2.0MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation September 2015' and contains detailed information about the company's clinical programs, development strategies, market opportunities, and clinical trial progress. It includes disclaimers typical of investor presentations and focuses on product pipelines and clinical data rather than financial statements or regulatory filings. There is no indication that this is an annual report, earnings release, or regulatory filing. The length is substantial (15,000 characters), and the content is consistent with a presentation aimed at investors to inform them about the company's strategy and progress. Therefore, the document fits the category of an Investor Presentation (IP).
2015-09-06 English
Appendix 3B - issue of placement shares and options 12 pages 537.4KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to these securities. The content includes detailed information about the class and number of securities issued, terms of the securities, issue price, purpose of the issue, and compliance with ASX listing rules. It is not a financial report, earnings release, or management discussion but rather a formal announcement of a capital raising event and securities issuance. This fits the definition of a Capital/Financing Update (CAP) filing, as it provides updates on company fundraising and capital structure changes.
2015-09-02 English
Placement - information required under LR3.10.5A 2 pages 243.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 3 September 2015 regarding the completion of a private placement by Invion Limited. It details the raising of approximately AU$1 million through the issue of shares and options, including terms of the options and conditions such as shareholder approval for some options. The content focuses on fundraising activities and capital structure changes, specifically a private placement and issuance of options. There is no indication that this is a full financial report, audit, or earnings release. The document is relatively short (3040 characters) and is a direct announcement of financing activity. Therefore, it fits the category of Capital/Financing Update (CAP).
2015-09-02 English
Notice under s708A Corporations Act - cleasning notice 1
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708A of the Corporations Act regarding the issue of shares and options by Invion Limited. It confirms the issuance of securities without disclosure under part 6D.2 of the Corporations Act and compliance with relevant provisions. The content is an announcement about a capital raising event and issuance of securities, not a full financial report or detailed financing update. Given the nature of the announcement about share issuance and options, it fits best under Capital/Financing Update (CAP). The document is short and specific to a financing event, not a full report or regulatory filing. Confidence is high due to clear references to share issuance and compliance with capital raising regulations.
2015-09-02 English
Invion completes placement to institutional US investor 2 pages 265.4KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Invion Limited regarding a private placement of shares and options to a US institutional investor. It details the terms of the placement, the number of shares and options to be issued, the expected closing date, and the intended use of proceeds. It also mentions shareholder approval required for some options at the upcoming Annual General Meeting. The content focuses on fundraising and capital raising activities, with no financial statements or detailed financial performance data included. The document length is about 5,320 characters, which is sufficient for a detailed announcement but does not constitute a full financial report. Therefore, this document fits the category of a Capital/Financing Update (CAP).
2015-08-31 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.